摘要
目的:探讨血清胸苷激酶1(thymidine kinase1,TK1)检测对乳腺癌辅助诊断及术后化疗效果评估的意义。方法:应用免疫印迹—增强化学发光法(ECL)检测48例乳腺肿瘤患者的血清TK1水平,并对其中随访1～3个月的14例术后化疗的血清TK1水平进行检测。结果:10例完成4～6个周期化疗后的血清TK1降低并接近正常人水平,4例血清TK1未降反升。随访1年后,有1例发生骨转移。结论:血清TK1水平反映细胞增殖,与病灶大小有一定相关性,连续跟踪结果有利于对乳腺癌治疗效果的辅助诊断,对临床监视肿瘤疗效具有临床意义。
Objective：To evaluate the serum thymidine kinase 1（TK1）as a tumor marker for early tumor detection and monitoring chemotherapy effect on breast cancer patients operated.Methods：A sensitive chemiluminescence dot-blot assay was used to detect serum TK1 level in breast cancer patients（48 cases）,including post-treated breast cancer patients（14 cases）.Results：Forty eight cases had the pathological stage data.In order to exam the effect of chemotherapy,14 cases were chose to be followed-up for 1～3 months.Serous TK1 level in 10 of 14 cases was decreased to the level of healthy volunteers;four in 14 cases had a increased serous TK1 level,and one of them progressed bone metastasis one year later.Conclusion：Serous TK1 level has a correlation to the proliferation of breast cancer cell.Serum TK1 is a favorable and helpful marker for monitoring the response of chemotherapy.
出处
《南京医科大学学报（自然科学版）》
CAS
CSCD
北大核心
2010年第7期1002-1004,共3页
Journal of Nanjing Medical University(Natural Sciences)
关键词
血清胸苷激酶1
乳腺癌
化疗
serum thymidine kanese 1
breast cancer
chemotherapy
